Related by context. All words. (Click for frequent words.) 78 ENMD # 75 Traficet EN 74 Azedra 74 Sym# 74 oral prodrug 74 AEG# 74 ALN TTR 74 PDE4 inhibitor 73 PEG SN# 73 DXL# 73 XmAb# 73 MEK inhibitor 73 PRT# 73 cMET 73 protein kinase inhibitor 72 pharmacodynamic profiles 72 Blinatumomab 72 R#/MEM # 72 HQK 72 HCD# [002] 72 ganetespib 72 Dasatinib 72 HuLuc# 72 proteasome inhibitor 72 MEK inhibitors 72 PSMA ADC 72 mertansine 72 Xanafide 72 CRLX# 72 Symadex 72 investigational humanized monoclonal antibody 72 orally administered inhibitor 72 CCR9 antagonist 72 fosbretabulin 72 HGS ETR2 71 ALN VSP 71 HCV protease inhibitor 71 CYT# potent vascular disrupting 71 Factor VIIa 71 INCB# [001] 71 Archexin 71 OXi# 71 systemic RNAi therapeutic 71 Triolex 71 CBLC# 71 OvaRex R 71 CR# vcMMAE 71 MAGE A3 ASCI 71 selective androgen receptor modulator 71 Panzem R 71 CIMZIA ™ 71 OncoVEX 71 IMA# 71 metaglidasen 71 receptor tyrosine kinase inhibitor 71 tezampanel 71 Nanobody 71 pertuzumab 71 rxRNA 71 Elagolix 71 glucagon receptor 71 CORT # 71 TKM ApoB 71 elotuzumab 70 Angiocept 70 preclinical efficacy 70 ALN PCS 70 PS# [001] 70 Carfilzomib 70 BiTE antibody 70 YONDELIS 70 ALN TTR# 70 HGS ETR1 70 Tezampanel 70 Virulizin ® 70 RGB # 70 liposomal formulation 70 OMP #M# 70 vascular disrupting agent 70 vidofludimus 70 CA4P 70 pan HDAC inhibitor 70 cannabinor 70 Aurora Kinase 70 sodium glucose cotransporter 70 HGS# 70 OncoVEX GM CSF 70 alvespimycin 70 Bezielle 70 CEQ# 70 preclinically 70 Tyrima 70 OMNARIS HFA 70 Nanobodies 70 PSN# [002] 69 vascular disrupting agents 69 Talabostat 69 A3 adenosine receptor 69 JVRS 69 Guanilib 69 Aplidin R 69 antiangiogenic activity 69 mecamylamine 69 generation antisense 69 Phase Ib study 69 GAMMAGARD 69 #ME# 69 plasma kallikrein inhibitor 69 cleavable linker 69 Mipomersen 69 HCV protease 69 Rigel R# 69 HER1 69 favorable pharmacokinetic profile 69 anti CD3 69 Dapagliflozin 69 GLP toxicology studies 69 MET amplification 69 huC# DM4 69 Solazed TM 69 Alocrest 69 orally bioavailable 69 Pimavanserin 69 XmAb 69 Exelixis compounds 69 DEB# 69 Bortezomib 69 Aurexis 69 LEP ETU 69 PRTX 69 rhIL 7 69 JAK1 69 Vidofludimus 69 polymerase inhibitor 69 APOPTONE 69 multi kinase inhibitor 69 antagomirs 69 riociguat 69 Anticalins 69 dexpramipexole 69 TACI Ig 69 Aliskiren 69 IAP inhibitor 69 TPI ASM8 69 antiangiogenic agents 69 Trastuzumab 69 tanespimycin 69 candidate CRLX# 69 TBC# 69 Epidermal Growth Factor Receptor 69 Prednisporin 69 rNAPc2 69 ATL# [001] 69 Androxal TM 69 Glufosfamide 69 NEUGENE 69 mapatumumab 69 Anticalins R 69 BRAF inhibitor 69 IRX 2 69 PI3K/mTOR 69 TLK# 69 volociximab 69 Phase 2b Clinical Trial 69 MYDICAR ® 69 INT# [002] 69 HuMax EGFr 69 Litx 69 novel VDA molecule 69 oxidative stress inducer 69 JAK inhibitor 69 Radezolid 68 Bendavia 68 CCR2 68 trastuzumab DM1 T DM1 68 TOLAMBA 68 Sphingomab 68 Tyrosine Kinase Inhibitor 68 highly selective inhibitor 68 anti amnesic 68 VA# [002] 68 BiTE 68 alpha folate receptor 68 HSP# inhibitor 68 #D#C# 68 obatoclax 68 Squalamine 68 systemically administered 68 EDEMA3 trial 68 Interferon alpha 68 novel peptide 68 Tamibarotene 68 Nanobody ® 68 ularitide 68 GRN# 68 SAR# [002] 68 histone deacetylase HDAC 68 CD# antibody [001] 68 GRNVAC1 68 small molecule tyrosine 68 LHRH antagonists 68 pradefovir 68 BAL# [002] 68 antisense oligonucleotides 68 erlotinib Tarceva ® 68 Phase #b/#a trial 68 SERMs 68 PEGylated interferon 68 oral picoplatin 68 indibulin 68 siRNA therapeutic 68 BHT DNA 68 CD# monoclonal antibody 68 Panzem R NCD 68 TRAIL receptor antibodies 68 EZN 68 phase IIb clinical 68 XP# XP# 68 protein tyrosine phosphatase 1B 68 EGFR HER2 68 investigational monoclonal antibody 68 investigational therapies 68 torezolid phosphate 68 PLK1 SNALP 68 Amrubicin 68 selective inhibition 68 Aflibercept 68 TLR9 agonist 68 Pralatrexate 68 novel histone deacetylase 68 PXD# 68 anticancer compound 68 somatostatin analogue 68 Dalbavancin 68 XL# XL# 68 teriflunomide 68 Degarelix 68 pomalidomide 68 bortezomib Velcade 68 GSK# [001] 68 myelofibrosis polycythemia vera 68 XL# XL# XL# XL# 68 maximally tolerated dose 68 NXL# 68 chemically modified siRNA 68 phase IIa clinical 68 Telatinib 68 BRAF kinase 68 PI3K inhibitor 68 oral gallium 68 peripherally acting 68 targeted radiotherapeutic 68 RNAi Therapeutic 68 mGluR5 NAM 68 Safinamide 68 neuroprotective properties 68 atacicept 68 JAK inhibitors 68 HDAC Inhibitor 68 BrachySil 68 thalidomide Thalomid 68 Sapacitabine 68 LEX System 68 CINQUIL 68 effector function 68 HuMax CD4 68 Hsp# Inhibitor 68 Onconase 68 Alzhemed TM 68 radiation sensitizer 68 AAG geldanamycin analog 68 Phase 2a trial 68 Belimumab 68 CCX# B 68 Ozarelix 68 orally dosed 68 nonclinical studies 68 CCR5 antagonist 68 JAK2 inhibitors 68 Xencor XmAb 68 Thiarabine 68 RAV# 68 Aurora kinase 68 proteasome inhibitors 68 HCV protease inhibitors 68 Panzem 67 Zoraxel TM 67 PNP inhibitor 67 TriRima 67 ALN HTT 67 Azedra ™ 67 ALK inhibitor 67 generation antisense inhibitor 67 kinase inhibition 67 MAXY G# 67 oral JAK1 67 MEK Inhibitor 67 IFN α 67 radezolid 67 pharmacodynamic properties 67 histone deacetylase HDAC inhibitor 67 CDK inhibitor 67 GVAX ® 67 Elotuzumab 67 EOquin 67 TKB# 67 PEGylated Fab fragment 67 vivo potency 67 RLY# 67 ARIKACE ™ 67 CIMZIA TM 67 Pertuzumab 67 tyrosine kinase inhibitor 67 squalamine 67 MGCD# [001] 67 dacetuzumab 67 Tesetaxel 67 MAP# 67 Meets Primary Endpoint 67 peptide antigens 67 Protexia R 67 Bafetinib 67 ZOLINZA 67 Trofex 67 non nucleoside HCV 67 Tarvacin TM 67 oncolytic vaccine 67 CCR5 mAb 67 OHR/AVR# 67 reslizumab 67 Spiegelmer ® 67 Exelixis XL# 67 Azedra TM 67 K ras mutations 67 P#X# 67 SCH # 67 Zolinza 67 5 HT3 antagonist 67 Lenocta 67 molecularly targeted 67 Tarceva TM 67 Eg5 67 Multimeric 67 DCVax R 67 delafloxacin 67 Liposomal 67 EDEMA3 67 immunomodulation 67 gemcitabine Gemzar 67 Anticalin R 67 ISF# 67 ON #.Na 67 VAPRISOL 67 CTAP# Capsules 67 LNP formulations 67 TG# [003] 67 docetaxel Taxotere ® 67 Kinase Inhibitor 67 PEGPH# 67 NOX E# 67 Onalta ™ 67 Inhalation Solution 67 non nucleoside 67 Debio 67 Ridaforolimus 67 Romidepsin 67 TRX1 67 selective kinase inhibitor 67 LY# [002] 67 Enzastaurin 67 teduglutide 67 ZK EPO 67 TRO# 67 VitiGam 67 Hsp# inhibitor 67 nucleoside analog 67 targeting CD# 67 selective orally bioavailable 67 multitargeted 67 Angiolix 67 relapsed MM 67 Allovectin 7 R 67 EGFr 67 nicotinic acetylcholine receptor 67 dasatinib Sprycel ® 67 Anticalin ® 67 INCB# [003] 67 IgG1 antibody 67 Oral NKTR 67 PI3K/Akt pathway inhibitor 67 TRIOLEX 67 T#I [002] 67 Tarvacin 67 CCR9 67 Anticalins ® 67 CGEN # 67 lintuzumab 67 evaluating tivozanib 67 GMX# 67 IAP inhibitors 67 Tofacitinib 67 CCR2 receptor 67 Cloretazine ® 67 huN# DM1 67 GAP #B# 67 ESBA# 67 Zemiva ™ 67 forodesine 67 Seliciclib 67 MKC# MKC# PP 67 XOMA 3AB 67 oral proteasome inhibitor 67 AP# [003] 67 REG1 67 TAFA# 67 MGd 67 Metastatic Melanoma 67 Ophena TM 67 Chemophase 67 biologic therapeutics 67 elacytarabine 67 ARRY # 67 ATL/TV# 67 DiLA2 67 Maribavir 67 luteinizing hormone releasing 67 KNS # 67 JAK2 inhibitor 67 uricase 67 Nanobodies ® 67 immunomodulator 67 Alfacell proprietary ribonuclease 67 HGS ETR1 mapatumumab 67 DOS# 67 5 HT2C receptor 67 Cethromycin 67 NEUMUNE 67 Zoraxel 67 JAK3 67 enzastaurin 67 dextofisopam 67 siRNA therapeutics 67 Cloretazine VNP#M 67 ISIS # 67 Perifosine 67 SIRT1 activators 67 IMC #B 67 MYDICAR 67 Aganocide 67 NS4A 67 DXL TM 67 otelixizumab 67 small molecule Hedgehog 67 humanized anti 67 selective modulator 66 Omacetaxine 66 Aganocide R 66 Plicera 66 Iluvien ® 66 tumor xenograft models 66 Proxinium TM 66 LY# [003] 66 Phase #b/#a clinical 66 Solorel TM 66 rBChE 66 DAVANAT 66 EGFR inhibitors 66 small molecule defensin 66 GRN#L 66 depsipeptide 66 GALNS 66 pathophysiological effects 66 octreotide implant 66 Tasimelteon 66 thymalfasin 66 EndoTAG TM -1 66 Pradefovir 66 antisense oligonucleotide 66 AeroLEF TM 66 peptidomimetic 66 direct thrombin inhibitors 66 RhuDex ® 66 CYC# 66 Soliris eculizumab 66 SAR# [004] 66 talabostat 66 immunoconjugate 66 HDAC inhibition 66 Zybrestat 66 humanized monoclonal antibody 66 virus HCV protease inhibitor 66 Kahalalide F 66 plasmid DNA vaccine 66 Revimmune 66 BAL# [001] 66 Epratuzumab 66 Golimumab 66 TRC# 66 mTOR inhibitors 66 MT#/MEDI-# 66 miRview mets 66 PANVAC VF 66 Preclinical studies suggest 66 humanized antibody 66 CD3 monoclonal antibody 66 dasatinib Sprycel 66 cobiprostone 66 HuMax CD# 66 Voreloxin 66 ocular formulation 66 Phase 2a Clinical Trial 66 immunotherapeutic agent 66 budesonide foam 66 PREOS R 66 ELACYT 66 IMC A# 66 pharmacodynamic PD 66 anti angiogenic drugs 66 investigational antibody 66 Panitumumab 66 DexaSite 66 novel nucleoside analog 66 sd rxRNA 66 immune stimulatory 66 TOCOSOL Camptothecin 66 interferon lambda 66 Capesaris 66 OMNARIS Nasal Spray 66 immunotherapeutic vaccine 66 Apoptone 66 MNTX 66 Epanova 66 LymphoStat B belimumab 66 IMiD 66 TNFa 66 tubulin inhibitor 66 LT NS# 66 trastuzumab Herceptin 66 FLT3 66 recurrent glioma 66 BZL# 66 TRAIL R2 66 Annamycin 66 nucleotide analog 66 PI3K inhibitors 66 alefacept 66 IL# PE#QQR 66 Fidaxomicin 66 biomarker identification 66 CD# CEA 66 Chemokine Receptor 66 Boceprevir 66 trastuzumab Herceptin R 66 Anavex #-# 66 Deforolimus 66 AEGR 66 anti angiogenic agent 66 GLYX 66 ART# 66 Cannabinor 66 regorafenib 66 Phase 1a clinical 66 CANCIDAS 66 adecatumumab 66 APTIVUS r 66 metastatic CRC 66 HuMax CD#b 66 Bicifadine 66 GnRH antagonist 66 assessing T DM1 66 REP# 66 humanized monoclonal 66 dimebon latrepirdine 66 Hedgehog inhibitor 66 Alfimeprase 66 tumor antigen 66 Interferon Gamma 66 VersaFilm 66 Systemic Delivery 66 MAb 66 nanopharmaceutical 66 delta isoform 66 EP #R 66 galiximab 66 Solazed ™ 66 Imprime PGG 66 SPC# [001] 66 histone deacetylase inhibitor 66 synthetic retinoid 66 Personalized Immunotherapy 66 Stedivaze 66 vascular disrupting 66 5 HT6 receptor 66 #beta HSD1 66 Preclinical Data 66 Cerashield 66 S/GSK# 66 Curaxin CBLC# 66 therapeutic monoclonal antibody 66 CINTREDEKIN BESUDOTOX 66 Civacir 66 synthetic siRNA 66 pharmacokinetic interactions 66 PDE4 inhibitors 66 Zysolin TM 66 specific lectin receptors 66 Anti Tumor 66 selective antagonist 66 DU #b 66 flavopiridol 66 Pharmos proprietary 66 chemokine receptor 66 Phase III Clinical Trial 66 urocortin 2 66 inhibit EGFR 66 Valortim R 66 NNR Therapeutics 66 Immunotherapeutic 66 INCB# [002] 66 Icatibant 66 HDL Selective Delipidation 66 investigational HCV polymerase 66 iSONEP 66 sipuleucel T 66 ZFP TF 66 JAK Inhibitor 66 IMPDH inhibitor 66 kidney urologic 66 Amplimexon 66 BioVant 66 Anthim 66 eTag assays 66 Phase 1b clinical trials 66 GFT# 66 ALN RSV# 66 Varespladib 66 generation Hsp# inhibitor 66 AIR# [001] 66 apremilast 66 MLN# 66 anticancer activity 66 Vitaxin 66 Genasense ® oblimersen 66 Enhanze Technology 66 Synavive ™ 66 NPC 1C 66 antibody fragment 66 Trofex TM 66 Src inhibitors 66 Cardiotoxicity 66 AKT inhibitor 66 rALLy 66 AMD# [003] 66 VDAs 66 Randomized Phase 66 potent antitumor activity 66 LHRH antagonist 66 Alnylam #x# 66 DDP# 66 5 HT6 66 oncolytic 66 inhibitor RG# 66 5 HT2A inverse 66 antisense inhibitors 66 p# biomarker 66 pharmacodynamic effects 66 MVA BN R 66 FGFR 66 Gastrointestinal Stromal Tumors 66 Tarmogen 66 MyVax R 66 ceftazidime 66 Bavituximab 66 Daclizumab 66 targeted antifolate 66 compound AEZS 65 DermaVir Patch 65 alpha#beta# integrin 65 HIF PH inhibitors 65 DP b# 65 cytostatic 65 Novel Oral 65 MDV# 65 Antiangiogenic 65 gefitinib Iressa 65 ospemifene 65 Presents Preclinical Data 65 Darinaparsin 65 delivers fluocinolone acetonide FA 65 lexidronam injection 65 Hsp# inhibition 65 KSP inhibitor 65 torezolid 65 Epothilones 65 Universal Flu Vaccine 65 XL# anticancer compounds 65 ChronVac C R 65 Ophena 65 HERmark 65 hormone LHRH antagonist 65 ALGRX 65 BAY #-# 65 Exherin TM 65 lapatinib Tykerb 65 viral kinetics 65 Serdaxin 65 Pivotal Phase 65 metastatic neuroendocrine tumors 65 HIV integrase inhibitors 65 Besivance 65 Antiviral Activity 65 Methylnaltrexone 65 lesinurad 65 trastuzumab Herceptin ® 65 PHX# 65 Cloretazine R VNP#M 65 bactericidal activity 65 TELINTRA 65 PROCHYMAL 65 MKC# MT 65 Tumor Response 65 neratinib 65 5 HT2B receptor 65 zanolimumab 65 R roscovitine 65 Phase Ib clinical 65 anti EGFR antibody 65 OvaRex ® MAb 65 tyrosine kinase inhibitor TKI 65 Beta catenin pathway 65 GSK# [002] 65 Neuradiab 65 florbetaben 65 oral bioavailability 65 candidate deforolimus 65 antisense drug 65 Monoclonal Antibody 65 vivo validation 65 cilengitide 65 Milatuzumab 65 ApoB SNALP 65 SNT MC# 65 PORxin TM 65 nilotinib Tasigna ® 65 humanised monoclonal antibody 65 ALN HPN 65 Ceplene/IL-2 65 BRIM2 65 INC# 65 ongoing Phase 1b 65 Neurodex 65 TLR9 agonists 65 Aplidin 65 prostanoid 65 PROVENGE sipuleucel T 65 ASONEP 65 anticoagulant reversing agent 65 Gleevec resistant 65 SYN# 65 alkylating agent 65 PROSTASCINT R 65 mTOR inhibitor 65 brostallicin 65 replicon 65 AzaSite TM 65 TRV# [001] 65 GW# [003] 65 epothilone 65 refractory prostate cancer 65 product candidate Lpathomab 65 HepaSphere 65 Sudhir Agrawal D.Phil 65 thrombopoietin 65 sunitinib Sutent ® 65 JAK#/JAK# 65 docetaxel Taxotere R 65 Fleximer 65 TLR7 65 potent anti angiogenic 65 AzaSite Plus 65 SNALP technology 65 PCK# 65 CRx 65 Glypromate 65 gamma secretase inhibitor 65 Vilazodone 65 IND submission 65 epothilones 65 XL# XL# XL# 65 Cloretazine R 65 bevacizumab Avastin ® 65 B7 H3 65 trastuzumab emtansine T DM1 65 HCV NS5B polymerase 65 Q#IR 65 omacetaxine mepesuccinate 65 Zemiva TM 65 polymerase inhibitors 65 Novolimus 65 ADP receptor antagonist 65 ALV# 65 silico prediction 65 Delafloxacin 65 Phase #/#a trial 65 lomitapide 65 Iloperidone 65 LHRH 65 agonistic human 65 oral renin inhibitor 65 glycosylation profile 65 MOZOBIL 65 generation nucleoside analog 65 telaprevir VX 65 cytoprotective 65 Synavive 65 mGluR2 NAM 65 QuadraSphere 65 CCR1 65 mGluR5 antagonist 65 antiangiogenic agent 65 PRX# 65 AQ4N 65 Phase III Pivotal 65 tipifarnib 65 orally bioavailable mimics 65 pharmacokinetic properties 65 liposomal doxorubicin 65 HCV polymerase 65 CYP#A# CYP#D# 65 menadione 65 Temsirolimus 65 GPNMB 65 tiapamil 65 potent antiproliferative 65 Protein Kinase C 65 TELCYTA 65 Vicinium TM 65 HCV SPRINT 65 sitaxsentan 65 RIGScan CR 65 small molecule activators 65 Vaxfectin 65 pharmacokinetic characteristics 65 Anticalin 65 Shigamabs ® 65 BCR ABL inhibitors 65 hypoxia inducible factor 65 LE DT 65 Atiprimod 65 telomerase therapeutic 65 superficial bladder cancer 65 PARP inhibitor 65 humanized monoclonal antibodies 65 pharmacokinetic PK profile 65 Actilon 65 FOLOTYN ® 65 visilizumab 65 Zemplar Capsules 65 Valortim ® 65 soluble receptor 65 mu opioid receptor antagonist 65 RELOVAIR ™ 65 Excellarate 65 IFN beta 65 SRT# [003] 65 UPLYSO 65 antiproliferative effects 65 Marqibo TM 65 novel anticancer 65 miR #a [002] 65 EOquin TM 65 cytotoxic agents 65 Altastaph 65 MAXY alpha 65 oncolytic virus therapies 65 Hedgehog pathway inhibitor 65 CCR5 inhibitor 65 Panzem NCD 65 TLR agonists 65 Phase 2a clinical trials 65 omega interferon 65 Optiquel ™ 65 VEGF receptor 65 oral taxane 65 NGX# 65 Targretin 65 IMiDs ® 65 SinuNase TM 65 immune modulating 65 nalbuphine ER 65 solithromycin 65 immunomodulatory 65 Denufosol 65 SPRYCEL ® 65 POTELLIGENT ® 65 p# inhibitor 65 anti CD# antibodies 65 vinca alkaloid 65 immunostimulatory 65 ISTODAX 65 retapamulin 65 posaconazole 65 APTIVUS 65 dosing cohort 65 oral FTY# 65 active moiety 65 Dose Escalation 65 diarrhea predominant irritable 65 Antitumor Activity 65 ONCONASE R 65 FBPase 65 microtubule inhibitor 65 Phase III Clinical Trials 65 R#/MEM 65 RhuDex R 65 AZD# 65 XL# inhibits 65 CXCR4 receptor 65 TLR8 65 PTP 1B 65 castrate resistant prostate cancer 65 TOCOSOL Paclitaxel 65 Janus kinase 65 TLR antagonist 65 Bevacizumab 65 trodusquemine 65 davunetide intranasal AL 65 HER3 65 rilonacept 65 Locteron 65 Combo Stent 65 5 HT4 receptor 65 cediranib 65 Erlotinib 65 PLX# 65 Aurora kinase inhibitor 65 Cetrorelix 65 leading oral taxane 65 plasma pharmacokinetics 65 ProSavin 65 EndoTAG TM 65 pharmacologic agents 65 Myocet 65 alemtuzumab Campath 65 pegylated interferons 65 Reports Preclinical Data 65 pro angiogenic 65 dosage regimens 65 ADAGIO study 65 potent inhibition 65 Trastuzumab DM1 65 PKC# 65 M2 subunit 65 NeuVax 65 adenosine receptor 65 lucinactant 65 cancer immunotherapies 65 decitabine 65 MORAb 65 bispecific antibody 65 diabetic neuropathic pain 64 ToGA 64 Telbivudine 64 recombinant subunit vaccine 64 Factor Receptor 64 axitinib 64 molecular biomarkers 64 LymphoStat B TM 64 Onalta 64 tumor necrosis 64 Immunomodulatory 64 small molecule agonists 64 Intravenous Human 64 NS#/#A protease 64 MetMAb 64 Chrysalin 64 Aclidinium 64 LymphoStat B 64 antitumor activity 64 nucleoside analogues 64 LibiGel ® 64 Fludarabine 64 Tumour Vascular Disrupting Agent 64 Pazopanib 64 XmAb ® 64 NNRTIs 64 proprietary LNA 64 SARMs 64 FVIIa 64 eosinophilic asthma 64 IMGN# 64 Randomized Double blind 64 ThermoDox ® clinical 64 non nucleoside inhibitor 64 cetuximab Erbitux R 64 anticancer agent 64 PEG Interferon lambda 64 beta lactamase inhibitor 64 goserelin